(A) Schematic of recombinant EphA2-FL, EphA2-NF and stem portion. FLAG-tag was added at C-terminus. (B) These recombinant proteins were detected by anti-FLAG mAb and anti-EphA2-N-termius pAb.
Funding
Abbott Laboratories (Abbott)
Japan Agency for Medical Research and Development (AMED)
MEXT | Japan Society for the Promotion of Science (JSPS)
Princess Takamatsu Cancer Research Fund
History
ARTICLE ABSTRACT
EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.